Safety of sapropterin dihydrochloride (6r–bh4) in patients with pulmonary hypertension

REFERENCES

• Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:13S–24S.
   PubMed Web of Science ®Google Scholar
• Cella G, Bellotto F, Tona F, Sbarai A, Mazzaro G, Motta G, Fareed J: Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest. 2001;120:1226–1230.
   PubMed Web of Science ®Google Scholar
• Stamler JS, Loh E, Roddy MA, Currie KE, Creager MA: Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 1994;89: 2035–2040.
   PubMed Web of Science ®Google Scholar
• Demoncheaux EA, Higenbottam TW, Kiely DG, Wong JM, Wharton S, Varcoe R, Siddons T, Spivey AC, Hall K, Gize AP: Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. J Vasc Res. 2005;42:133–136.
   PubMed Web of Science ®Google Scholar
• Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT: Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med. 2005;172:352–357.
   PubMed Web of Science ®Google Scholar
• Rolla G, Colagrande P, Scappaticci E, Chiavassa G, Dutto L, Cannizzo S, Bucca C, Morello M, Bergerone S, Bardini D, Zaccagna A, Puiatti P, Fava C, Cortese G: Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension. J Rheumatol. 2000;27:1693–1698.
   PubMed Web of Science ®Google Scholar
• Kaneko FT, Arroliga AC, Dweik RA, Comhair SA, Laskowski D, Oppedisano R, Thomassen MJ, Erzurum SC: Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. Am J Respir Crit Care Med. 1998;158:917–923.
   PubMed Web of Science ®Google Scholar
• Andrew PJ, Mayer B: Enzymatic function of nitric oxide synthases. Cardiovasc Res. 1999;43:521–531.
   PubMed Web of Science ®Google Scholar
• Palmer RM, Ashton DS, Moncada S: Vascular endothelial cells synthesize nitric oxide from l-arginine. Nature. 1998;333:664–666.
   Google Scholar
• Katusic ZS: Vascular endothelial dysfunction: does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol. 2001;281:H981–H986.
   PubMed Web of Science ®Google Scholar
• Khoo JP, Zhao L, Alp NJ, Bendall JK, Nicoli T, Rockett K, Wilkins MR, Channon KM: Pivotal role for endothelial tetrahydrobiopterin in pulmonary hypertension. Circulation. 2005;111:2126–2133.
   PubMed Web of Science ®Google Scholar
• Robbins IM, Morrow JD, Christman BW: Oxidant stress but not thromboxane decreases with epoprostenol therapy. Free Radic Biol Med. 2005;38:568–554.
   PubMed Web of Science ®Google Scholar
• Bowers R, Cool C, Morphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF: Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med. 2004;169:764–769.
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Cracowski C, Bessard G, Pepin JL, Bessard J, Schwebel C, Stanke-Labesque F, Pison C: Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med. 2001;164:1038–1042.
   PubMed Web of Science ®Google Scholar
• Zhao YY, Zhao YD, Mirza MK, Huang JH, Potula HH, Vogel SM, Brovkovych V, Yuan JX, Wharton J, Malik AB: Persistent eNOS activation secondary to caveolin-1 deficiency induces pulmonary hypertension in mice and humans through PKG nitration. J Clin Invest. 2009;119:2009–2018.
   PubMed Web of Science ®Google Scholar
• Heitzer T, Krohn K, Albers S, Meinertz T: Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res. 2000;86:E36–E41.
   PubMed Web of Science ®Google Scholar
• Higashi Y, Sasaki S, Nakagawa K, Fukuda Y, Matsuura H, Oshima T, Chayama K: Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens. 2001;15:326–332.
   Web of Science ®Google Scholar
• Setoguchi S, Mohri M, Shimokawa H, Takeshita, A: Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J Am Coll Cardiol. 2001;38:493–498.
   PubMed Web of Science ®Google Scholar
• Muntau AC, Röschinger W, Habich M, Demmelmair H, Hoffmann B, Sommerhoff CP, Roscher AA: Tetrahydrobiopterin as an alternative treatment for mild phenylketonuria. N Engl J Med. 2002;347:2122–2132.
   PubMed Web of Science ®Google Scholar
• Cerone R, Schiaffino MC, Fantasia AR, Perfumo M, Birk Moller L, Blau N: Long-term follow-up of a patient with mild tetrahydrobiopterin-responsive phenylketonuria. Mol Genet Metab. 2004;81:137–139.
   PubMed Web of Science ®Google Scholar
• ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories: ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166:111–117.
   PubMed Web of Science ®Google Scholar
• Sebbag I, Rudski LG, Therrien J, Hirsch A, Langleben D: Effect of chronic infusion of epoprostenol on echocardiographic right ventricular myocardial performance index and its relation to clinical outcome in patients with primary pulmonary hypertension. Am J Cardiol. 2001;88:1060–1063.
   PubMed Web of Science ®Google Scholar
• Itoh T, Nagaya N, Ishibashi-Ueda H, Kyotani S, Oya H, Sakamaki F, Kimura H, Nakanishi N: Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension. Respirology. 2006;11:158–163.
   PubMed Web of Science ®Google Scholar
• Girgis RE, Champion HC, Diette GB, Johns RA, Permutt S, Sylvester JT. Decreased exhaled nitric oxide in pulmonary arterial hypertension: response to bosentan therapy. Am J Respir Crit Care Med. 2005;172:352–357.
   PubMed Web of Science ®Google Scholar
• Cella G, Bellotto F, Tona F, Sbarai A, Mazzaro G, Motta G, Fareed J. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest. 2001;120:1226–1230.
   PubMed Web of Science ®Google Scholar
• Bogdan M, Humbert M, Francoual J, Claise C, Duroux P, Simonneau G, Lindenbaum A. Urinary cGMP concentrations in severe primary pulmonary hypertension. Thorax. 1998;53:1059–1062
   PubMed Web of Science ®Google Scholar
• American Thoracic Society; European Respiratory Society: ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171:912–930.
   PubMed Web of Science ®Google Scholar
• Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation. 2001;104:424–428.
   PubMed Web of Science ®Google Scholar
• Milne GL, Sanchez SC, Musiek ES, Morrow JD: Quantification of F2-isoprostanes as a biomarker of oxidative stress. Nat Protoc. 2007;2:221–226.
   PubMed Web of Science ®Google Scholar
• Cheitlin MD, Hutter AM Jr, Brindis RG, Ganz P, Kaul S, Russell RO Jr, Zusman RM: Use of sildenafil (Viagra) in patients with cardiovascular disease. ACC/AHA Expert Consensus Document. Circulation. 1999;99:168–177.
   Google Scholar
• Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G: Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148–2157.
   PubMed Web of Science ®Google Scholar
• Galiè N, Brundage BH, Ghofrani HA, Oudiz RJ, Simonneau G, Safdar Z, Shapiro S, White RJ, Chan M, Beardsworth A, Frumkin L, Barst RJ: Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group: Tadalafil therapy for pulmonary arterial hypertension. Circulation. 2009;119:2894–2903.
   PubMed Web of Science ®Google Scholar
• McLaughlin VV, Oudiz RJ, Frost A, Tapson VF, Murali S, Channick RN, Badesch DB, Barst RJ, Hsu HH, Rubin LJ: Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257–1263.
   PubMed Web of Science ®Google Scholar
• Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, Harrison DG: Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001;103:1282–1288.
   PubMed Web of Science ®Google Scholar
• Xue C, Johns RA: Endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1995;333:1642–1644.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, Badesch D, Voelkel NF: Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925–1932.
   PubMed Web of Science ®Google Scholar
• Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, Goggans T, Thunnissen FB, Farver C, Hazen SL, Jennings C, Dweik RA, Arroliga AC, Erzurum SC: Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J. 2004;18:1746–1748.
   PubMed Web of Science ®Google Scholar
• Higashi Y, Sasaki S, Nakagawa K, Fukuda Y, Matsuura H, Oshima T, Chayama K: Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens. 2001;15:326–332.
   Web of Science ®Google Scholar
• Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398–2403.
   PubMed Web of Science ®Google Scholar
• Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ: Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group: Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:2127–2134.
   PubMed Web of Science ®Google Scholar